SCHEMBL4386502

SCHEMBL4386502

Cc1c(C(F)(F)F)ccnc1C(C)C

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.32
DHODH Q02127 1/20 0.32
HDAC6 Q9UBN7 1/20 0.32
AAK1 Q2M2I8 5/20 0.32
TRPM8 Q7Z2W7 1/20 0.32
CYP1A2 P05177 2/20 0.31
CYP3A4 P08684 2/20 0.31
ALOX15 P16050 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
HIF1A Q16665 1/20 0.31
HSD17B10 Q99714 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
ALDH1A1 P00352 1/20 0.31
CYP2C19 P33261 1/20 0.31
HRH4 Q9H3N8 2/20 0.31
HSD11B1 P28845 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13058560 0.81 PDE2A (0.36) AAK1TRPM8CYP1A2CYP3A4ALOX15
SCHEMBL30154950 0.79 HRH4 (0.38) AAK1TRPM8CYP1A2CYP3A4ALOX15
SCHEMBL20285912 0.79 P2RX7 (0.42) AAK1TRPM8CYP1A2CYP3A4ALOX15
SCHEMBL4386496 0.79 LRRK2 (0.32) TRPM8CYP1A2CYP3A4ALOX15TSHR
SCHEMBL21542799 0.79 HRH4 (0.38) AAK1TRPM8CYP1A2CYP3A4ALOX15
SCHEMBL25703635 0.78 AAK1 (0.30) AAK1TRPM8
SCHEMBL22623126 0.77 CYP3A4 (0.38) TRPM8CYP1A2CYP3A4ALOX15MAPK1
SCHEMBL21092875 0.77 CYP1A2 (0.38) ARCYP1A2CYP3A4ALOX15TSHR
SCHEMBL4547925 0.76 TRPM8 (0.47) TRPM8HSD11B1
SCHEMBL30547062 0.75 DHODH (0.35) ARDHODHHDAC6CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629342-B2 Regulation of appetite, antiemetics, immunosuppression, analgesia, inflammation, antinocioception, sedation, and intraocular pressure; synergistic; 2-(4-(Trifluoromethyl)benzyl)-7,8-bis(4-chlorophenyl)-6-(methylamino)-[1,2,4]triazolo[4,3-b]pyridazin-3(2H)-one BRISTOL-MYERS SQUIBB COMPANY (US) 2009-12-08 US claimed
US-20180170948-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF Bio TheryX, Inc. 2018-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180170948-A1 COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF CKS1B, IKZF3, EPAS1 AR 1479/4885DHODH 4183/4885HDAC6 1057/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.